The $3.5 Billion Miscalculation In 2011, Warner Chilcott and Allergan settled a Paragraph IV lawsuit over the branded proton pump […]

The Five-Year Window Is Not Generous When a branded drug loses patent exclusivity, its manufacturer does not get to negotiate

How generic and 505(b)(2) developers mine expired and lapsed pharmaceutical patents for low-cost market entry The drug development world has

The Patent Cliff Is Real, and So Is the Industry’s Response Every pharmaceutical executive knows the feeling. A blockbuster drug

The pharmaceutical industry manages intellectual property through three disconnected systems. The Food and Drug Administration (FDA) maintains the Orange Book

Every year, dozens of pharmaceutical patents expire quietly. A few dozen more get abandoned before they even reach their full

The pharmaceutical industry is trapped in a pincer movement. On one side, the cost of developing a new molecular entity

Introduction: The Graveyard With a Pulse Every year, thousands of pharmaceutical patents die quietly. No press release. No analyst call.

Why CIS Patent Terms Confuse Even Experienced IP Professionals When a pharmaceutical company’s legal team maps out its global IP